Imiquimod 5% Cream for Keloid Management

Berman, Brian; Villa, Adriana M.

doi:10.1046/j.1524-4725.2003.29300.x

Cited by 42 publications

(23 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a dose-dependent inhibition of human fibroblast collagen production by interferon α and γ, by decreasing the production of both collagen and glycosaminoglycans [17,18]. Due to imiquimod’s ability to increase the local production of interferon after topical application, it has been successfully used to treat and prevent keloid scar recurrence [19]. In view of the same mechanism, it has been proposed as a therapeutic option for fibromatoses and sclerodermoid conditions [20].…”

Section: Discussionmentioning

confidence: 99%

Topical Imiquimod 5% Cream for Pediatric Plaque Morphea: A Prospective, Multiple-Baseline, Open-Label Pilot Study

Pope

Doria²,

Theriault³

et al. 2011

Dermatology

View full text Add to dashboard Cite

Background/Aims: Therapeutic options for the treatment of plaque morphea are limited. We explored the efficacy and safety of imiquimod cream in children with plaque morphea. Methods: Prospective, open-label, double-baseline study, using imiquimod 5% cream topically for 9 months. The primary outcome measure was improvement in the thickening of morphea plaques using a visual analog scale (VAS) and the DIET score (dyspigmentation/induration/erythema/telangiectasia). Secondary outcome measures were clinicoradiographic correlations and frequency of adverse events. Results: Nine patients, 89% females, with a mean age of 11.33 years (SD = 3.52) were enrolled. At 36 weeks, the mean VAS had decreased from 48.08 (SD = 18.85) to 22.7 (SD = 12.9) (p < 0.0001), and the mean DIET score from 4.38 (SD = 1.2) to 3.06 (SD = 1.39) (p = 0.23). There was very good interrater reliability between DIET score assessments (intraclass correlation coefficient, ICC = 0.75) and VAS (ICC = 0.59) and moderate agreement between parent and investigator VAS (ICC = 0.5). Ultrasonographically measured dermis thickness changed from 1.05 (SD = 0.34) to 0.95 (SD = 0.19) (p = 0.001). One patient experienced ulceration that required temporary discontinuation of intervention. Conclusions: This proof of concept study revealed that imiquimod 5% cream is effective in decreasing the thickening of plaque morphea and safe for pediatric use. Further prospective studies are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Topical Imiquimod 5% Cream for Pediatric Plaque Morphea: A Prospective, Multiple-Baseline, Open-Label Pilot Study

Pope

Doria²,

Theriault³

et al. 2011

Dermatology

View full text Add to dashboard Cite

show abstract

“…[102][103] One study examined the effects of postoperative appli- cation of imiquimod to 13 keloids surgically excised from 12 patients. The cream was applied nightly for 8 weeks, starting on the night of the surgery.…”

Section: Keloidsmentioning

confidence: 99%

Viral and Nonviral Uses of Imiquimod: A Review

2004

View full text Add to dashboard Cite

show abstract

“…Furthermore, corticosteroids, an immunosuppressive agent, have been used as a treatment for KD as well as psoriasis, which is an inXammatory disorder of the skin with pathogenesis that have considerable overlap with other human inXammatory or autoimmune diseases [6,16,28]. Post-surgical application of imiquimod, which is a topical immunomodulator, has also been reported to have reduced the recurrence rate in KD [3,27]. Our study suggest a possible involvement of HLA-DRB5 in the development of KD through minor puncture wounds; if further research can clarify the mechanism of action for this association, potential gene-speciWc classiWcation of KD and tailored treatments may be developed for KD patients carrying this susceptibility gene.…”

Section: Discussionmentioning

confidence: 99%

Comparative genomic hybridisation analysis of keloid tissue in Caucasians suggests possible involvement of HLA-DRB5 in disease pathogenesis

Shih

Bayat

2011

Arch Dermatol Res

View full text Add to dashboard Cite

Keloid disease (KD) is a common fibroproliferative disorder that can occur following cutaneous injury in genetically susceptible individuals. Familial predisposition, high prevalence in certain populations and occurrence in twins suggest a strong genetic component to KD. However, to date no single causative gene has been identified. Copy number variations (CNVs) in genes have been associated with several human diseases including common skin disorders. The objective of this study was, therefore to determine if CNVs in the human genome may contribute to the development of KD. Agilent SurePrint G3 one Million microarrays were used to detect DNA copy number differences in keloid scars of four Caucasian females and compared to commercial reference DNA samples. Subsequent validation was performed with quantitative polymerase chain reactions (qPCR) using 15 KD cases and 27 Caucasian controls. Further validation using a second cohort was carried out with an additional 11 Caucasian controls and 10 KD cases developed from minor skin puncture wounds (caused by acne, vaccination or chickenpox). HLA-DRB1*15 was typed using allele-specific primers in PCR. Five CNV regions located at chromosome (chr) 6p21.32, chr11q11, chr17q12, chr8p23.1, chr22q13.1, chr19p13.1 and chr2q14.3 were selected for validation with qPCR. When comparing controls to subgroups of KD, according to their cause of scarring, chr6p21.32 (primer design targetting HLA-DRB5) was significantly (P < 0.005) associated with KD developed from minor skin puncture wounds, which is further validated using a larger sample size (P < 0.001). The presence of HLA-DRB5 was associated with HLA-DRB1*15 status; 18 out of 19 individuals were positive for both HLA-DRB5 and HLA-DRB1*15 allele. In conclusion, these preliminary findings further support the possible contribution of the HLA genes in KD pathogenesis.

show abstract

Imiquimod 5% Cream for Keloid Management

Abstract: Topical application of imiquimod 5% cream after surgery reduces keloid recurrences.

Cited by 42 publications

References 6 publications

Topical Imiquimod 5% Cream for Pediatric Plaque Morphea: A Prospective, Multiple-Baseline, Open-Label Pilot Study

Topical Imiquimod 5% Cream for Pediatric Plaque Morphea: A Prospective, Multiple-Baseline, Open-Label Pilot Study

Viral and Nonviral Uses of Imiquimod: A Review

Comparative genomic hybridisation analysis of keloid tissue in Caucasians suggests possible involvement of HLA-DRB5 in disease pathogenesis

Contact Info

Product

Resources

About